DE3584817D1 - Verfahren zur herstellung vom therapeutisch nutzbaren fviii/vwf-komplex und resultierende produkte. - Google Patents

Verfahren zur herstellung vom therapeutisch nutzbaren fviii/vwf-komplex und resultierende produkte.

Info

Publication number
DE3584817D1
DE3584817D1 DE8585430031T DE3584817T DE3584817D1 DE 3584817 D1 DE3584817 D1 DE 3584817D1 DE 8585430031 T DE8585430031 T DE 8585430031T DE 3584817 T DE3584817 T DE 3584817T DE 3584817 D1 DE3584817 D1 DE 3584817D1
Authority
DE
Germany
Prior art keywords
fviii
producing
complex
vwf complex
vwf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8585430031T
Other languages
English (en)
Inventor
Alain Bourgois
Marylene Les Eaux Vive Delezay
Vincent Fert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Immuno AG fuer Chemisch Medizinische Produkte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG, Immuno AG fuer Chemisch Medizinische Produkte filed Critical Immuno AG
Application granted granted Critical
Publication of DE3584817D1 publication Critical patent/DE3584817D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16—ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16L—PIPES; JOINTS OR FITTINGS FOR PIPES; SUPPORTS FOR PIPES, CABLES OR PROTECTIVE TUBING; MEANS FOR THERMAL INSULATION IN GENERAL
    • F16L55/00—Devices or appurtenances for use in, or in connection with, pipes or pipe systems
    • F16L55/26—Pigs or moles, i.e. devices movable in a pipe or conduit with or without self-contained propulsion means
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04N—PICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N5/00—Details of television systems
    • H04N5/76—Television signal recording
    • H04N5/91—Television signal processing therefor
    • H04N5/92—Transformation of the television signal for recording, e.g. modulation, frequency changing; Inverse transformation for playback
    • H04N5/9201—Transformation of the television signal for recording, e.g. modulation, frequency changing; Inverse transformation for playback involving the multiplexing of an additional signal and the video signal
    • H04N5/9206—Transformation of the television signal for recording, e.g. modulation, frequency changing; Inverse transformation for playback involving the multiplexing of an additional signal and the video signal the additional signal being a character code signal
    • H04N5/9207—Transformation of the television signal for recording, e.g. modulation, frequency changing; Inverse transformation for playback involving the multiplexing of an additional signal and the video signal the additional signal being a character code signal for teletext
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mechanical Engineering (AREA)
  • Combustion & Propulsion (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Signal Processing (AREA)
  • Multimedia (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE8585430031T 1984-09-18 1985-09-17 Verfahren zur herstellung vom therapeutisch nutzbaren fviii/vwf-komplex und resultierende produkte. Expired - Lifetime DE3584817D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8414480A FR2570276B1 (fr) 1984-09-18 1984-09-18 Procede d'obtention du complexe fviii/vwf a usage therapeutique et produits en resultant

Publications (1)

Publication Number Publication Date
DE3584817D1 true DE3584817D1 (de) 1992-01-16

Family

ID=9307917

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585430031T Expired - Lifetime DE3584817D1 (de) 1984-09-18 1985-09-17 Verfahren zur herstellung vom therapeutisch nutzbaren fviii/vwf-komplex und resultierende produkte.

Country Status (9)

Country Link
US (1) US4670543A (de)
EP (1) EP0179006B1 (de)
JP (2) JPH0649720B2 (de)
AT (1) ATE69955T1 (de)
CA (1) CA1257211A (de)
DE (1) DE3584817D1 (de)
ES (1) ES8700568A1 (de)
FR (1) FR2570276B1 (de)
WO (1) WO1986001718A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543145A (en) * 1984-09-17 1996-08-06 Baxter International, Inc. Pharmaceutical composition and method for the suppression of factor VIII inhibitor production
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
DE3707213A1 (de) * 1987-03-06 1988-09-15 Behringwerke Ag Verfahren zur herstellung von faktor viii:c-mangelplasma und ein so erhaltenes mangelplasma
US5177191A (en) * 1987-12-21 1993-01-05 Miles, Inc. Gel filtration of factor VIII
FR2632309B1 (fr) * 1988-06-07 1990-08-24 Lille Transfusion Sanguine Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
FR2665449B1 (fr) * 1990-08-02 1995-04-14 Aquitaine Developp Transf Sang Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant.
US5760183A (en) * 1989-02-17 1998-06-02 Association D'aquitaine Pour De Developpment De La Transfusion Sanguine Et Des Recherches Hematologiques Process for the manufacture of very high-purity antithaemophilic factor (FVIIIC), and von Willebrand factor, and pharmaceutical compositions containing same
US5110907A (en) * 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
JPH0427865A (ja) * 1989-12-21 1992-01-30 Kurita Water Ind Ltd 血液凝固因子用分離剤およびその製造方法
AT403991B (de) * 1990-04-04 1998-07-27 Atomic Austria Gmbh Alpinschi
AT403992B (de) * 1991-02-22 1998-07-27 Head Sport Ag Ski
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT403765B (de) * 1996-04-12 1998-05-25 Immuno Ag Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex
AT406867B (de) 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
US20060068454A1 (en) * 2004-09-27 2006-03-30 Sysmex Corporation Method of inactivating blood coagulation factor and blood coagulation factor-inactivated sample

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies

Also Published As

Publication number Publication date
US4670543A (en) 1987-06-02
WO1986001718A1 (fr) 1986-03-27
JPH0649720B2 (ja) 1994-06-29
FR2570276A1 (fr) 1986-03-21
JPS62500520A (ja) 1987-03-05
CA1257211A (fr) 1989-07-11
ES547051A0 (es) 1986-10-16
FR2570276B1 (fr) 1987-09-04
JPH06107700A (ja) 1994-04-19
ATE69955T1 (de) 1991-12-15
EP0179006A1 (de) 1986-04-23
ES8700568A1 (es) 1986-10-16
EP0179006B1 (de) 1991-12-04
JPH06102680B2 (ja) 1994-12-14

Similar Documents

Publication Publication Date Title
DE3584817D1 (de) Verfahren zur herstellung vom therapeutisch nutzbaren fviii/vwf-komplex und resultierende produkte.
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
DE3586536T3 (de) Monoklonaler Antikörper gegen ein Cytotoxin, denselben erzeugendes Hybridoma und Verfahren für die Herstellung des gereinigten Cytotoxin.
DE58902737D1 (de) Verfahren zur herstellung pharmazeutischer mischungen.
DE3689734D1 (de) Gereinigter immunoglobulinbezüglicher Faktor, monoklonale Antikörper, Hybridoma-Zellinien, Verfahren und Verwendungen.
DE2963977D1 (en) Antigen preparation, process for producing it and pharmacological or dental preparations containing the antigen preparation or antibodies thereto
MC1553A1 (fr) Proteine d'interferon immunitaire humain et son procede de production
DK382989D0 (da) Cytotoxiske vinca-konjugater bundet til antistoffer og fremgangsmaade til fremstilling deraf
ATA318081A (de) Verfahren zur herstellung von topischen verfahren zur herstellung von topischen pharmazeutischen zubereitungen pharmazeutischen zubereitungen
FI870502A (fi) Menetelmä ristisuojaavien ihmisen monoklonaalisten vasta-aineiden valmistamiseksi ja vasta-ainetta tuottava solulinja
ATA111789A (de) Humaner monoklonaler antikörper und hybridom zur herstellung desselben
DE69220113T2 (de) Verfahren zur Herstellung von menschlichem Serum Albumin
AT360184B (de) Verfahren zur herstellung von neuen pentapep- tiden, deren c-terminalen estern und amiden sowie von deren salzen
DE3689868D1 (de) Monoklonale Antikörper gegen menschliches Plasma-Prekallikrein und Verfahren zu ihrer Herstellung und Verwendung.
AT360678B (de) Verfahren zur herstellung von neuen angiotensin -ii-antagonistisch wirkenden peptiden sowie von deren saeureadditionssalzen und komplexen
EP0185391A3 (en) Method for the purification of the hbc antigen and method for the measurement of hbc antibodies by using said purified hbc antigen
ATA803679A (de) Verfahren zur herstellung galenischer zubereitungen
NO178893C (no) Fremgangsmåte for fremstilling av antistoff mot sykdomspatogen
ATE4282T1 (de) Verfahren zur herstellung von toxoplasmenbereitungen fuer die toxoplasmosediagnose und die so hergestellten bereitungen.
ATA198383A (de) Verfahren zur herstellung von praeparationen aus menschlichem blutplasma
AU7485987A (en) Method for producing monoclonal antibodies to an immunogenic antibody-antigen conjunction
ATE144286T1 (de) Monoklonale antikörper gegen den plasmin- antiplasmin komplex, verfahren zu ihrer herstellung sowie ihre verwendung
HUT48678A (en) Process for producing lym-1 mouse hybridoma and diagnostic antibody therefrom
ATA298784A (de) Verfahren zur herstellung neuer kondensierter as-triazinium-derivate sowie von deren isomeren
IT7851059A0 (it) Procedimento per la produzione di immunoglobuline in particolare di gammaglobuline purificate per uso endovenoso e gammaglobuline prodotte

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee